Rockefeller Capital Management
DYN icon

Rockefeller Capital Management’s Dyne Therapeutics DYN Stock Holding History

Rockefeller Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Sell
14,278
-883
-6% -$16.4K ﹤0.01% 2336
2026
Q1 		$275K Buy
15,161
+893
+6% +$15.4K ﹤0.01% 2306
2025
Q4 		$279K Buy
14,268
+5,730
+67% +$109K ﹤0.01% 2193
2025
Q3 		$108K Buy
+8,538
New +$97.4K ﹤0.01% 2550

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Rockefeller Capital Management's DYN Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Dyne Therapeutics (DYN) stake by 5.8% in Q2 2026, selling an estimated $16.4K and leaving 14,278 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

Rockefeller Capital Management first reported a position in DYN in Q3 2025 and has held it in 4 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Rockefeller Capital Management held 14,278 shares of Dyne Therapeutics worth $317K as of Q2 2026.
  • Rockefeller Capital Management sold 883 Dyne Therapeutics shares in Q2 2026, an estimated $16.4K.
  • Dyne Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2336 holding.
  • Rockefeller Capital Management first reported a position in Dyne Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.